Liquidia Corporation is set to proceed with the commercial launch of its inhalation powder, YUTREPIA, following a legal victory against United Therapeutics. On May 30, 2025, the U.S. District Court for the Middle District of North Carolina denied United Therapeutics' request for a preliminary injunction and a temporary restraining order. United Therapeutics had sought to block Liquidia from commercializing YUTREPIA, alleging infringement of their patent. The court's decision was influenced by the conclusion that United Therapeutics is unlikely to succeed on the merits of its claims. With the denial of this request, Liquidia is clear to begin shipping YUTREPIA to specialty pharmacies, just days after receiving FDA approval for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。